Merck & Co., Inc. (LON:0QAH)

Market Cap	148.81B
Revenue (ttm)	49.47B
Net Income (ttm)	13.49B
Shares Out	n/a
EPS (ttm)	5.32
PE Ratio	11.03
Forward PE	9.01
Dividend	2.44 (3.02%)
Ex-Dividend Date	Jun 16, 2025

Volume	13,741
Average Volume	13,449
Open	82.60
Previous Close	82.15
Day's Range	80.83 - 82.65
52-Week Range	73.30 - 129.95
Beta	0.40
RSI	54.58
Earnings Date	Jul 29, 2025

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janu...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1891
• Employees: 75,000
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QAH

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD